DURECT Corporation (DRRX): Price and Financial Metrics


DURECT Corporation (DRRX)

Today's Latest Price: $1.71 USD

0.04 (-2.29%)

Updated Sep 30 4:00pm

Add DRRX to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 239 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

DRRX Stock Summary

  • With a one year PEG ratio of 186.98, Durect Corp is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 83.31% of US stocks.
  • Price to trailing twelve month operating cash flow for DRRX is currently 311.73, higher than 98.94% of US stocks with positive operating cash flow.
  • As for revenue growth, note that DRRX's revenue has grown 153.13% over the past 12 months; that beats the revenue growth of 96.19% of US companies in our set.
  • Stocks that are quantitatively similar to DRRX, based on their financial statements, market capitalization, and price volatility, are EXEL, ESPR, TNAV, CRUS, and SMCI.
  • DRRX's SEC filings can be seen here. And to visit Durect Corp's official web site, go to www.durect.com.
DRRX Daily Price Range
DRRX 52-Week Price Range

DRRX Stock Price Chart Technical Analysis Charts


DRRX Price/Volume Stats

Current price $1.71 52-week high $3.95
Prev. close $1.75 52-week low $0.95
Day low $1.69 Volume 735,028
Day high $1.78 Avg. volume 1,426,292
50-day MA $1.96 Dividend yield N/A
200-day MA $2.08 Market Cap 342.99M

DURECT Corporation (DRRX) Company Bio


DURECT Corporation, a specialty pharmaceutical company, focuses on the development of pharmaceuticals products based on its proprietary drug formulations and delivery platform technologies in the United States, Europe, Japan, and internationally. The company was founded in 1998 and is based in Cupertino, California.

DRRX Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$1.71$0.02 -99%

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Durect Corp. To summarize, we found that Durect Corp ranked in the 3th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. In terms of the factors that were most noteworthy in this DCF analysis for DRRX, they are:

  • Its compound free cash flow growth rate, as measured over the past 2.24 years, is -0.04% -- higher than only 20.04% of stocks in our DCF forecasting set.
  • As a business, Durect Corp experienced a tax rate of about 0% over the past twelve months; relative to its sector (Healthcare), this tax rate is higher than merely 0% of stocks generating free cash flow.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-99%
1%-99%
2%-99%
3%-99%
4%-99%
5%-99%

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as DRRX, try AGHC, AHPI, ALC, AMRN, and DRAD.


DRRX Latest News Stream


Event/Time News Detail
Loading, please wait...

DRRX Latest Social Stream


Loading social stream, please wait...

View Full DRRX Social Stream

Latest DRRX News From Around the Web

Below are the latest news stories about Durect Corp that investors may wish to consider to help them evaluate DRRX as an investment opportunity.

Durect (DRRX) Investor Presentation - Slideshow

The following slide deck was published by DURECT Corporation in conjunction with this event....

SA Transcripts on Seeking Alpha | August 28, 2020

DURECT Corporation (DRRX) CEO Jim Brown on Q2 2020 Results - Earnings Call Transcript

DURECT Corporation (DRRX) Q2 2020 Earnings Conference Call August 03, 2020 04:30 PM ET Company Participants Mike Arenberg - Chief Financial Officer Jim Brown - President & Chief Executive Officer WeiQi Lin - Executive Vice President, Research & Development & Principal Scientist Conference Call Participants Ellie Merle - Cantor Fitzgerald...

SA Transcripts on Seeking Alpha | August 4, 2020

Is It Too Late to Buy These 3 Pharmaceutical Stocks?

Relmada Therapeutics, Neoleukin Therapeutics, and Durect were among the fastest-rising pharmaceutical stocks over the past year.

Yahoo | July 7, 2020

DURECT Corporation Announces Initiation of Patient Recruitment in Phase 2 Safety and Efficacy Study of DUR-928 in COVID-19 Patients with Acute Liver or Kidney Injury

DURECT Corporation (Nasdaq: DRRX) today announced it has initiated recruiting patients for its randomized, double-blind, placebo-controlled, multi-center Phase 2 study to evaluate the safety and efficacy of DUR-928 in hospitalized COVID-19 infected patients with acute liver or kidney injury. The primary efficacy endpoint is a composite of survival and being free of acute organ failure at Day 28. The trial will enroll approximately 80 patients.

Yahoo | July 1, 2020

DURECT Corporation Joins the Russell 3000® Index

DURECT Corporation (Nasdaq: DRRX) today announced that it is set to join the broad-market Russell 3000® Index as a result of the 2020 Russell indexes annual reconstitution, effective after the US stock market opens today, June 29, 2020.

Yahoo | June 29, 2020

Read More 'DRRX' Stories Here

DRRX Price Returns

1-mo -1.44%
3-mo -23.66%
6-mo 28.57%
1-year 1.18%
3-year -3.39%
5-year -17.39%
YTD -55.00%
2019 691.67%
2018 -47.83%
2017 -31.34%
2016 -39.37%
2015 179.75%

Continue Researching DRRX

Here are a few links from around the web to help you further your research on Durect Corp's stock as an investment opportunity:

Durect Corp (DRRX) Stock Price | Nasdaq
Durect Corp (DRRX) Stock Quote, History and News - Yahoo Finance
Durect Corp (DRRX) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7538 seconds.